Loading
Genomics and Rare Diseases / CRISPR and Genetic Engineering · Journal article
Discover Genetics and Evolution · September 9, 2026
A consensus or society position rather than new primary data.
This is a narrative review examining the molecular mechanisms, prediction methods, and experimental detection approaches for off-target cleavage across three major programmable nuclease platforms (ZFNs, TALENs, CRISPR-Cas systems) and emerging editing modalities. The review consolidates current knowledge on specificity challenges and mitigation strategies but does not report original experimental or clinical evidence of efficacy or safety.
Journal article.
Off-target activity is identified as a significant challenge in clinical development of CRISPR-based therapies, with mismatch tolerance governed by PAM sampling, seed region thermodynamics, and chromatin accessibility. In silico prediction methods range from early alignment-based approaches through machine learning models to deep learning architectures, with identified limitations in training data, cross-platform generalisability, and distinction between exhaustive search and predictive scoring. Experimental detection landscape includes established and newer unbiased genome-wide assays with varying sensitivity and suitability for structural variant detection.
No quantitative efficacy or safety data reported; review is qualitative and synthesizes existing literature.
Clinicians and researchers evaluating or developing CRISPR-based therapies should use this review as a resource for understanding mechanistic drivers of off-target activity, comparative strengths and limitations of prediction and detection methods, and current best practices for safety characterization. The review highlights that standardization and surveillance of structural variants remain incomplete across the expanding diversity of editing platforms.
A comprehensive narrative review synthesizing mechanistic knowledge, detection methods, and safety mitigation strategies for off-target effects across CRISPR platforms—intended to inform clinical development and standardization rather than to report original data.
Clinicians and researchers evaluating or developing CRISPR-based therapies should use this review as a resource for understanding mechanistic drivers of off-target activity, comparative strengths and limitations of prediction and detection methods, and current best practices for safety characterization. The review highlights that standardization and surveillance of structural variants remain incomplete across the expanding diversity of editing platforms.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Off-target activity remains a significant challenge in the clinical development of CRISPR-based therapies. As programmable nucleases advance from experimental tools toward approved medicines, the ability to predict, detect, and mitigate unintended genomic editing events has acquired direct translational importance. This review examines the molecular basis of off-target cleavage across three nuclease platforms—zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas systems—with emphasis on mechanistic and structural factors that govern mismatch tolerance, including PAM sampling, seed region thermodynamics, and chromatin accessibility. In silico prediction methods are surveyed from early alignment-based approaches through feature-engineered machine learning models to more recent deep learning architectures, with critical attention to training data limitations, cross-platform generalisability, and the distinction between exhaustive genomic search tools and predictive scoring models. The experimental detection landscape is reviewed with expanded coverage of established and newer unbiased genome-wide assays, including their biological principles, sensitivity characteristics, and suitability for structural variant detection. Particular attention is given to next-generation editing modalities—base editors, prime editors, and Cas12/Cas13 systems—and to epigenome editing approaches using non-cleaving CRISPR platforms, which avoid double-strand breaks but retain specificity concerns. The review also addresses delivery-related off-target risks, including tissue-level biodistribution and germline exposure, alongside mitigation strategies. It closes by outlining directions for improving standardisation, expanding structural variation surveillance, and extending safety characterisation to the full diversity of editing platforms now approaching clinical use.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.